Pathogen inactivation: Coming of age

Current Opinion in Hematology

Volumn 20, Issue 6, 2013, Pages 540-545

  Lozano, Miguel ^a   Cid, Joan ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

fresh frozen plasma; pathogen inactivation; plasma; platelet concentrates; platelets

Indexed keywords

ALPHA 2 ANTIPLASMIN; AMOTOSALEN; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; COMPLEMENT FACTOR; FIBRINOGEN; FRESH FROZEN PLASMA; METHYLENE BLUE; PLASMIN INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEIN S; RIBOFLAVIN; SOLVENT; THROMBOCYTE CONCENTRATE; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

BLOOD COMPONENT; FREEZE THAWING; HEART SURGERY; HUMAN; ILLUMINATION; LIGHT; LIPID BILAYER; PATHOGENESIS; PLASMA; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE TRANSFUSION; THROMBOEMBOLISM; ULTRAVIOLET C RADIATION;

BLOOD COMPONENT TRANSFUSION; BLOOD PLATELETS; BLOOD SAFETY; BLOOD-BORNE PATHOGENS; DISINFECTION; ERYTHROCYTES; HUMANS; INFECTION CONTROL;

EID: 84885417252     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e328365a18f     Document Type: Review

References (57)

1. Lozano M, Cid J. Analysis of reasons for not implementing pathogen inactiva-tion for platelet concentrates. Transfus Clin Biol 2013; 20:158-164.
2. Lambrecht B, Mohr H, Knuver-Hopf J, Schmitt H. Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light. Vox Sang 1991; 60:207-213.
3. Zeiler T, Riess H, Wittmann G, et al. The effect of methylene blue photo-treatment on plasma proteins and in vitro coagulation capability of singledonor fresh-frozen plasma. Transfusion 1994; 34:685-689.
4. Aznar JA, Bonanad S, Montoro JM, et al. Influence of methylene blue photoinactivation treatment on coagulation factors from fresh frozen plasma, cryoprecipitates and cryosupernatants. Vox Sang 2000; 79:156-160.
5. Williamson LM, Cardigan R, Prowse CV. Methylene blue-treated fresh-frozen plasma: what is its contribution to blood safety? Transfusion 2003; 43:1322-1329.
6. Wieding JU, Rathgeber J, Zenker D, et al. Prospective, randomized and controlled study solvent/detergent versus methylene blue/light virus inactivated plasma. AABB Annual Meeting. San Francisco, CA. Transfusion 1999; 39 (Suppl):23S.
7. Bartelmaos T, Chabanel A, Leger J, et al. Plasma transfusion in liver trans-plantation: a randomized, double-blind, multicenter clinical comparison of three virally secured plasmas. Transfusion 2013; 53:1335-1345.
8. Alvarez-Larran A, Del Rio J, Ramirez C, et al. Methylene blue-photoinacti-vated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Vox Sang 2004; 86:246-251.
9. Rio-Garma J, Alvarez-Larran A, Martinez C, et al. Methylene blue-photoinacti-vated plasma versus quarantine fresh frozen plasma in thrombotic thrombo-cytopenic purpura: a multicentric, prospective cohort study. Br J Haematol 2008; 143:39-45.
10. Lozano M, Cid J. Spain: methylene-blue plasma. In: AuBuchon JP, Prowse C, editors. Pathogen inactivation: the penultimate paradigm shift. Bethesda: AABB Press; 2010. pp. 181-188.
11. Nubret K, Delhoume M, Orsel I, et al. Anaphylactic shock to fresh-frozen plasma inactivated with methylene blue. Transfusion 2011; 51:125-128.
12. Dewachter P, Castro S, Nicaise-Roland P, et al. Anaphylactic reaction after methylene blue-treated plasma transfusion. Br J Anaesth 2011; 106:687-689.
13. Mertes PM, Demoly P, Alperovitch A, et al. Methylene blue-treated plasma: an increased allergy risk? J Allergy Clin Immunol 2012; 130:808-812.
14. L'Afssaps recommande l'arrêt progressif de l'utilisation du plasma thér-apeutique traité par le bleu de méthylè ne. October 2011. Availablet at http://ansm.sante.fr/S-informer/Points-d- information-Points-d-information/L-Afssaps-recommande-l-arret-progressif-de-l- utilisation-du-plasma-therapeu tique-traite-par-le-bleu-de-methylene-Point-d- information. [Accessed 12 July 2013]
15. Bost V, Odent-Malaure H, Chavarin P, et al. A regional haemovigilance retrospective study of four types of therapeutic plasma in a ten-year survey period in France. Vox Sang 2013; 104:337-341.
16. New H, Tinegate H, Hunt L, et al. Methylene blue-treated plasma. Joint UKBTS /HPA Professional Advisory Committee/Serious Hazards of Transfusion (SHOT) Position Statement. http://www.transfusionguidelines.org.uk/Index.aspx?pageid= 7737§ion=12&publication=DL. [Accessed 7 July 2013]
17. Horowitz B, Bonomo R, Prince AM, et al. Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood 1992; 79:826-831.
18. Hellstern P, Sachse H, Schwinn H, et al. Manufacture and in vitro characterization of a solvent/detergent-treated human plasma. Vox Sang 1992; 63:178-185.
19. Solheim BG, Cid J, Osselaer JC. Pathogen reduction technologies. In: Lozano M, Contreras M, Blajchman M, editors. Global perspective in transfusion medicine. Bethesda, MD: AABB Press; 2006. pp. 103-148.
20. Salge-Bartels U, Breitner-Ruddock S, Hunfeld A, et al. Are quality differences responsible for different adverse reactions reported for SD-plasma from USA and Europe? Transfus Med 2006; 16:266-275.
21. Hellstern P. Fresh-frozen plasma, pathogen-reduced single-donor plasma or bio-pharmaceutical plasma? Transfus Apher Sci 2008; 39:69-74.
22. Yarranton H, Cohen H, Pavord SR, et al. Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura. Br J Haematol 2003; 121:778-785.
23. Scully M, Longair I, Flynn M, et al. Cryosupernatant and solvent detergent fresh-frozen plasma (Octaplas) usage at a single centre in acute thrombotic thrombocytopenic purpura. Vox Sang 2007; 93:154-158.
24. Hellstern P, Solheim BG. The use of solvent/detergent treatment in pathogen reduction of plasma. Transfus Med Hemother 2011; 38:65-70.
25. Irsch J, Lin L. Pathogen inactivation of platelet and plasma blood components for transfusion using the INTERCEPT Blood System. Transfus Med Hemother 2011; 38:19-31.
26. Cid J, Ramiro L, Martinez N, et al. Quantitative and qualitative analysis of proteins in fresh frozen plasma obtained from whole blood donations and prepared with two photochemical treatments. Transfus Apher Sci 2008; 39:115-121.
27. Osselaer JC, Debry C, Goffaux M, et al. Coagulation function in fresh-frozen plasma prepared with two photochemical treatment methods: methylene blue and amotosalen. Transfusion 2008; 48:108-117.
28. Irsch J, Pinkoski L, Corash L, et al. INTERCEPT plasma: comparability with conventional fresh-frozen plasma based on coagulation function-an in vitro analysis. Vox Sang 2010; 98:47-55.
29. de Alarcon P, Benjamin R, Dugdale M, et al. Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies. Transfusion 2005; 45:1362-1372.
30. Mintz PD, Neff A, MacKenzie M, et al. A randomized, controlled phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. Transfusion 2006; 46:1693-1704.
31. Goodrich RP. The use of riboflavin for the inactivation of pathogens in blood products. Vox Sang 2000; 78 (Suppl 2):211-215.
32. Ruane PH, Edrich R, Gampp D, et al. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004; 44:877-885.
33. Cardo LJ, Salata J, Mendez J, et al. Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrates using riboflavin and ultraviolet light. Transfus Apher Sci 2007; 37:131-137.
34. Tonnetti L, Thorp AM, Reddy HL, et al. Evaluating pathogen reduction of Trypanosoma cruzi with riboflavin and ultraviolet light for whole blood. Transfusion 2012; 52:409-416.
35. Keil SD, Kiser P, Sullivan JJ, et al. Inactivation of Plasmodium spp. in plasma and platelet concentrates using riboflavin and ultraviolet light. Transfusion 2013; Jan 16. doi: 10.1111/trf.12079. [Epub ahead of print]
36. Hornsey VS, Drummond O, Morrison A, et al. Pathogen reduction of fresh plasma using riboflavin and ultraviolet light: effects on plasma coagulation proteins. Transfusion 2009; 49:2167-2172.
37. Seltsam A, Muller TH. UVC irradiation for pathogen reduction of platelet concentrates and plasma. Transfus Med Hemother 2011; 38:43-54.
38. Osselaer JC, Cazenave JP, Lambermont M, et al. An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment. Vox Sang 2008; 94:315-323.
39. Osselaer JC, Messe N, Hervig T, et al. A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment. Transfusion 2008; 48:1061-1071.
40. Cazenave JP, Isola H, Kientz D. Pathogen inactivation of platelets. In: Sweeney J, Lozano M, editors. Platelet transfusion therapy. Bethesda, MD: AABB Press; 2013.
41. van Rhenen DJ, Vermeij J, Mayaudon V, et al. Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coats. Vox Sang 2000; 79:206-214.
42. Picker SM, Speer R, Gathof BS. Functional characteristics of buffy-coat PLTs photochemically treated with amotosalen-HCl for pathogen inactivation. Transfusion 2004; 44:320-329.
43. 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light. Transfusion 2004; 44:1732-1740.
44. van Rhenen D, Gulliksson H, Cazenave JP, et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003; 101:2426-2433.
45. McCullough J, Vesole DH, Benjamin RJ, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT trial. Blood 2004; 104:1534-1541.
46. Lozano M, Knutson F, Tardivel R, et al. A multicentre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion. Br J Haematol 2011; 153:393-401.
47. Kerkhoffs JL, van Putten WL, Novotny VM, et al. Clinical effectiveness of leukoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol 2010; 150:209-217.
48. Slichter SJ, Kaufman RM, Assmann SF, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010; 362:600-613.
49. Vamvakas EC. Meta-analysis of the randomized controlled trials of the hemostatic efficacy and capacity of pathogen-reduced platelets. Transfusion 2011; 51:1058-1071.
50. Vamvakas EC. Meta-analysis of the studies of bleeding complications of platelets pathogen-reduced with the Intercept system. Vox Sang 2012; 102:302-316.
51. Cid J, Escolar G, Lozano M. Therapeutic efficacy of platelet components treated with amotosalen and ultraviolet A pathogen inactivation method: results of a meta-analysis of randomized controlled trials. Vox Sang 2012; 103:322-330.
52. Osselaer JC, Vandendaele M, Gulen T, et al. Influence on HLA alloimmunisa-tion frequency in hematology patients supported with Intercept pathogen inactivated (PI) platelet components (PC). Transfusion 2011; 51 (Suppl): 122A.
53. Galan AM, Lozano M, Molina P, et al. Impact of pathogen reduction technology and storage in platelet additive solutions on platelet function. Transfusion 2011; 51:808-815.
54. Marschner S, Goodrich R. Pathogen reduction technology treatment of platelets, plasma and whole blood using riboflavin and UV light. Transfus Med Hemother 2011; 38:8-18.
55. Li J, de Korte D, Woolum MD, et al. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products. Vox Sang 2004; 87:82-90.
56. Perez-Pujol S, Tonda R, Lozano M, et al. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Transfusion 2005; 45:911-919.
57. AuBuchon JP, Herschel L, Roger J, et al. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005; 45:1335-1341.